Home›Clinical trials›GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

A study testing whether a GLP-1 medicine, dulaglutide, can help people with cystic fibrosis lower blood sugar.

Recruiting now. Registry record last updated May 18, 2026.

Who can join
Adults 18+, have cystic fibrosis, BMI 19+.
What you take
Dulaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 7 years.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 2Sponsor University of PennsylvaniaDrug dulaglutideClass GLP-1 RASites 2 USEnrollment target 30

What this study is for

Primary condition: Cystic Fibrosis. Also studied in: Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes.

Full scientific study title: GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance.

Who can join

Age18 and upSexAnyBMI19 or higher

Adults 18+, have cystic fibrosis, BMI 19+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • 1\. Male or female, aged ≥18 years on date of consent
  • 2\. Confirmed diagnosis of CF, defined by positive sweat test or Cystic Fibrosis transmembrane conductance regulator (CFTR) mutation analysis according to Cystic Fibrosis Foundation (CFF) diagnostic criteria.
  • 3\. Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement.
  • 4\. Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD.
  • There will be no restriction on enrollment of individuals with CFRD but without fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose ≥126 mg/dL)

Key exclusion criteria

  • 1\. BMI \<19 kg/m2
  • 2\. Presence of first-degree atrioventricular block or other evidence for cardiac conduction system or structural heart defects
  • 3\. Pregnancy or lactation; a negative urine pregnancy test will be required at enrollment
  • 4\. Known allergic reactions to any GLP-1 agonist, and any history of severe hypersensitivity reactions (anaphylaxis or angioedema)
  • 5\. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2)

Where this trial is enrolling

This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.

Colorado1 site
Pennsylvania1 site

Timeline

Started enrolling: July 16, 2021. Expected completion: June 30, 2028. Last updated on ClinicalTrials.gov: May 18, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.